Our Leadership Team

Sara Chumbley, MBA, MA, Founder and Chief Executive Officer

Sara is a seasoned leader with over two decades of experience in drug development and commercialization, having contributed to the successful launch of 21 products across 27 indications, many of which were first-in-class therapies. Her progressively senior roles in Business Development, Medical Affairs, Commercial, and Project Management have equipped her with deep expertise in navigating the complexities of the pharmaceutical landscape while applying practical knowledge of best practices and risk mitigation.

Sara's diverse experience spans startups, biotechs, major pharmaceutical companies such as BMS and Novartis, and a global health non-profit. This breadth of experience allows her to approach challenges with a comprehensive understanding of various organizational structures and industry landscapes. She has a proven track record of success in remotely leading international teams and collaborating with companies across 18 countries, demonstrating her strength in cross-cultural communication and her ability to navigate diverse regulatory environments while tailoring solutions to meet local standards.

Before starting her own consultancy, Sara drove success as head of Business Development at a boutique biotech consulting firm. There, Sara thoughtfully built contract teams for more than 15 biotech startups. She also directly partnered with client C-suite teams on pivotal initiatives, including regulatory submissions, clinical trial execution, manufacturing oversight, supply chain management, and product commercialization.

Sara holds an MBA from Warwick Business School, University of Warwick.

Courtney Rutkowski, Founder and Chief Engagement Officer

With over 25 years of experience in healthcare and life sciences, Courtney excels in building commercial frameworks that attract top talent, foster innovation, and drive collaborative problem-solving.

Her strategic approach has consistently exceeded revenue expectations in over 10 novel therapeutic product launches, achieving accelerated timelines across multiple rare disease areas. She has successfully built multiple first-in-class sales organizations aligned with startup goals, driving rapid market traction and revenue growth. Leveraging her market expertise, Courtney consistently creates demand through targeted campaigns, ensuring swift market penetration.

By optimizing talent acquisition and leveraging a deep understanding of the market ecosystem, Courtney has demonstrated a strong aptitude for establishing high-performing teams that deliver immediate and sustained impact. Her skill in fostering cross-functional collaboration, aligning resources, and forming strategic partnerships maximizes revenue and ensures successful product launches, whether within minimal or extended timelines.

Stephanie Collins, RN, BSN, BCPA, Founder and Chief Patient Advocacy Officer

Stephanie is a visionary leader with over 30 years of experience in healthcare and life sciences, specializing in the commercialization of first-in-class therapies for specialty and rare diseases. As Chief Patient Advocacy Officer at Eido Bio, she brings her expertise in successfully launching 15 products, including groundbreaking advancements in women's health, to drive patient-centric strategies and ensure transformative therapies reach those who need them most. 

With a unique background in nursing and patient advocacy, Stephanie's career has been defined by her unwavering commitment to improving patient outcomes. She has consistently championed disease awareness campaigns and worked tirelessly to ensure that patients with rare and chronic conditions are seen, heard, and provided access to innovative treatments. Her leadership was instrumental in spearheading 15 successful product launches, including the first diagnostic and treatment paradigm shift for a common chronic disease in over a century. 

Stephanie's experience spans roles at leading companies such as Intermune, UCB, Vertex, BMS, Intercept, Insmed, and Provention Bio, where she has been pivotal in building and preparing markets for first-in-class therapies. Her active involvement with key industry organizations allows her to drive public policy and access initiatives, contributing to meaningful improvements in care quality and accessibility. Stephanie's multidisciplinary background in nursing, biology, and business, combined with her passion for bridging the gap between unmet needs and treatment, brings a unique, holistic perspective to Eido Bio's strategic initiatives, advancing the company's mission to deliver innovative therapies that address critical unmet needs and fill significant treatment gaps in patient care. 

Timothy Ayers, JD, MPH, General Counsel and Chief Legal Officer

Timothy Ayers has provided legal, compliance, and regulatory support to small and mid-size life science companies for over two decades. Specializing in rare diseases and oncology, Tim prides himself on providing practical and efficient in-house counsel for companies in the rare disease space or start-up phase across all types of life science companies, including device, biotech, and diagnostic companies. 

As Associate General Counsel at Abraxis Biosciences, he provided legal and compliance guidance. He supported the commercialization of Abraxane, overseeing corporate transactions globally and advising on PRC matters with the co-promote partner. At Allos Therapeutics, Tim was critical to Folotyn's prelaunch and launch activities as Compliance Officer and Associate General Counsel. He played a similar role at Seattle Genetics, where he supported the launch of Adcetris, creating supply chain logistics, establishing channels with a 3PL and Hub, and building the Compliance Program from scratch. Tim also assisted the business development team with contracting and potential partnerships. At Dendreon Corporation, Tim served as Chief Compliance Officer, where he relaunched and enhanced the company’s Compliance Program with a global scope while primarily focusing on domestic commercialization efforts.

More recently, Tim held the role of Chief Compliance Officer at Horizon Pharma, overseeing compliance across all business units globally. Since 2018, he has successfully built compliance programs and provided legal counsel for numerous biotech companies, including Karyopharm, Reata, BridgeBio, Dompé and CTI. He has also served as General Counsel for GeneDx and currently serves as such for Valorum Bio and Remi Therapeutics.

Tim holds a J.D. from Georgetown University and a Master of Public Health from Columbia University. Prior to his in-house roles, he worked in the healthcare group at Winston & Strawn, LLP in Washington, D.C.

''

Greg Schiffman, MBA, Board Member

Gregory Schiffman is an accomplished senior finance executive with more than 25 years of strategic and operational finance, treasury, corporate development, manufacturing and logistics experience.  Mr. Schiffman has been a CFO and an Independent Director of both public and private companies for over 20 years.

He was the CFO of ABSCI, taking them public through an IPO process in 2021, was the CFO at Vineti, Lion Biotechnologies, Inc., which has since been renamed Iovance Biotherapeutics, Inc., and served as Executive Vice President and CFO at StemCells, Inc., Dendreon Corp. and Affymetrix.  Prior to these roles, Mr. Schiffman was Vice President and Controller at Applied BioSystems where he managed global financial operations and at Hewlett Packard he headed up a variety of global assignments including international finance assignments in Europe and Asia, and was a VP of Manufacturing for a U.S. manufacturing operation. 

Mr. Schiffman received an M.B.A. from Northwestern University’s Kellogg School of Management, is a CPA and holds a bachelor’s degree in accounting from De Paul University.